Natural killer (NK) cell-based immunotherapies are attracting increasing interest in the field
of cancer treatment. Early clinical trials have shown promising outcomes, alongside …

Immunotherapy has rapidly evolved in the past decades in the battle against cancer.
Chimeric antigen receptor (CAR)-engineered T cells have demonstrated significant success …

Acute myeloid leukemia (AML) poses a singular challenge for chimeric antigen receptor
(CAR) therapy owing to its phenotypic heterogeneity and similarity to normal hematopoietic …

Background Relapsed or refractory acute myeloid leukemia (R/R AML) has a dismal
prognosis. The aim of this study was to investigate the activity and tolerability of venetoclax …

Natural Killer (NK) cells, intrinsic to the innate immune system, are pivotal in combating
cancer due to their independent cytotoxic capabilities in antitumor immune response. Unlike …

The tumor microenvironment (TME) is a highly intricate milieu, comprising a multitude of
components, including immune cells and stromal cells, that exert a profound influence on …

Natural killer (NK) cells, a unique component of the innate immune system, are inherent
killers of stressed and transformed cells. Based on their potent capacity to kill cancer cells …

Chimeric antigen receptor (CAR)-NK cell therapy has the advantages of a low incidence of
side effects and a low cost. However, the clinical outcomes are not satisfactory due to limited …

Cancer immunotherapy harnesses the body's immune system to combat malignancies,
building upon an understanding of tumor immunosurveillance and immune evasion …

Background The cytotoxicity of NK cells is largely dependent on IgG Fc receptor CD16a,
which mediates antibody-dependent cell-mediated cytotoxicity (ADCC). The high-affinity and …